SHEV

Stabilizing the exposure of neutralization epitopes on HIV-1 envelope glycoprotein trimer vaccines

 Coordinatore Academisch Medisch Centrum bij de Universiteit van Amsterdam 

Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.

 Nazionalità Coordinatore Netherlands [NL]
 Totale costo 1˙499˙943 €
 EC contributo 1˙499˙943 €
 Programma FP7-IDEAS-ERC
Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call ERC-2011-StG_20101109
 Funding Scheme ERC-SG
 Anno di inizio 2012
 Periodo (anno-mese-giorno) 2012-01-01   -   2016-12-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    Academisch Medisch Centrum bij de Universiteit van Amsterdam

 Organization address address: MEIBERGDREEF 9
city: AMSTERDAM
postcode: 1105AZ

contact info
Titolo: Dr.
Nome: Rogier Willem
Cognome: Sanders
Email: send email
Telefono: +31 20 56 65279
Fax: +31 20 56 69064

NL (AMSTERDAM) hostInstitution 1˙499˙943.00
2    Academisch Medisch Centrum bij de Universiteit van Amsterdam

 Organization address address: MEIBERGDREEF 9
city: AMSTERDAM
postcode: 1105AZ

contact info
Titolo: Ms.
Nome: Gulseren
Cognome: Yalvac
Email: send email
Telefono: +31 20 56 66265
Fax: +31 2056 69698

NL (AMSTERDAM) hostInstitution 1˙499˙943.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

immunogens    gp    inducing    cells    protein    hiv    conserved    vaccines    levels    vaccine    movement    antibodies    conformational    cell    neutralizing    causes    flexibility    env    world   

 Obiettivo del progetto (Objective)

'The impact of HIV/AIDS on world healthcare is tremendous, particularly in the Third World. To curtail the HIV epidemic a cheap and effective vaccine is urgently needed, but despite massive research efforts no vaccine is available yet. Although most vaccines work by inducing neutralizing antibodies, HIV has evolved many ways to limit the induction and binding of neutralizing antibodies. The challenge is to engineer Env subunit vaccines that do induce neutralizing antibodies efficiently. One aspect that has been highly underappreciated is conformational heterogeneity of Env. Conformational flexibility is exerted at three different levels. First, flexible variable loops and N-glycans protruding from the conserved protein core cause “local flexibility” at the protein surface. Second, movement between the conserved inner and outer domain of gp120 causes “tertiary flexibility”. Third, movement of the three gp120 protomers in the trimeric complex, resembling a flower that opens and closes, causes “quaternary flexibility”. These three levels of flexibility provide very unstable targets for recognition by low affinity B cell receptors on naïve B cells, diminishing the chance of efficient B cell activation and the secretion of neutralizing antibodies. Using a number of novel structure-based vaccine design strategies that include the introduction of stabilizing disulfide bonds, we intend to remove the undesirable flexibility on Env trimers to provide a homogeneous and stable target to B cells. This should result in stabilized Env immunogens that are better in inducing neutralizing antibodies compared to the current state-of-the art Env vaccines. This is a highly interdisciplinary project on the crossroads of immunology and protein chemistry and should result in protein immunogens that elicit improved neutralizing antibody responses against HIV and should provide answers to fundamental questions on how B cells “see” protein immunogens.'

Altri progetti dello stesso programma (FP7-IDEAS-ERC)

EC (2010)

Extremal Combinatorics

Read More  

NONEQ.STEEL (2012)

Controlling Non-Equilibrium in Steels

Read More  

WAYS (2013)

"Role of Liver Estrogen Receptor in female Energy Metabolism, Reproduction and Aging: What About Your Liver Sexual Functions?"

Read More